Midland Announces Closing of $6.1 Million Private Placement with Strategic Investment from Centerra Gold
As part of the private placement, Midland is pleased to welcome Centerra Gold Inc. ('Centerra') (TSX: CG) (NYSE: CGAU) as a new strategic investor. Centerra now holds approximately 9.9% of the Corporation's issued and outstanding common shares.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Charlotte's Web 2025 Second Quarter Earnings Call and Webcast Notice
LOUISVILLE, Colo., Aug. 5, 2025 /CNW/ - (TSX: CWEB) (OTC: CWBHF) Charlotte's Web Holdings, Inc. (" Charlotte ' s Web" or the " Company") a botanical wellness innovation company and the market leader in cannabidiol (CBD) hemp extract wellness products, will report its 2025 second quarter results prior to market open on August 13, 2025. A conference call to review the results is scheduled for the same day at 11:00 A.M. Eastern Time. There are three ways to join the call: Register and enter your phone number at to receive an instant automated call back, or Dial 1-646-357-8785 or 1-800-836-8184 approximately 10 minutes before the conference call, or Listen to the live webcast online. Earnings Call Replay A recording of the call will be available through August 20, 2025. To listen to a replay of the earnings call please dial 1- 646-517-4150 or 1-888-660-6345 and provide conference replay ID 22439#. A webcast of the call will also be accessible through the investor relations section of the Company's website for an extended period of time. Subscribe to Charlotte's Web investor news. About Charlotte's Web Holdings, Inc. Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in Louisville, Colorado, is a botanical wellness innovation company and a market leader in hemp extract wellness that includes Charlotte's Web whole-plant full-spectrum CBD extracts as well as broad-spectrum CBD and cannabinoid isolates. The Company's hemp extracts have naturally occurring botanical compounds including cannabidiol ("CBD"), CBN, CBC, CBG, THC, terpenes, flavonoids, and other beneficial compounds. Charlotte's Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, calming, exercise recovery, immunity), CBN gummies, hemp-derived THC microdose gummies, functional mushroom gummies, CBD capsules, CBD topical creams, and lotions, as well as CBD pet products for dogs. Through its substantially vertically integrated business model, Charlotte's Web maintains stringent control over product quality and consistency with analytic testing from soil to shelf for quality assurance. Charlotte's Web products are distributed to retailers and healthcare practitioners throughout the U.S.A. and are available online through the Company's website at
Winnipeg Free Press
an hour ago
- Winnipeg Free Press
S&P/TSX composite starts the week on the rise while U.S. markets fall
TORONTO – Canada's main stock index started the trading week on an upswing while U.S. markets fell. The S&P/TSX composite index was up 426.23 points at 27,446.66. In New York, the Dow Jones industrial average was down 142.46 points at 44,031.18. The S&P 500 index was down 27.46 points at 6,302.60, while the Nasdaq composite was down 85.98 points at 20,967.61. The Canadian dollar traded for 72.52 cents US compared with 72.53 cents US on Friday. The September crude oil contract was down 80 cents US at US$65.49 per barrel. Monday Mornings The latest local business news and a lookahead to the coming week. The December gold contract was up US$15.80 at US$3,442.20 an ounce. This report by The Canadian Press was first published Aug. 5, 2025.
Globe and Mail
2 hours ago
- Globe and Mail
If You'd Invested $1,000 in PFE 5 Years Ago, Here's How Much You'd Have Today
Key Points Pfizer's stock is down over 60% from its December 2021 peak (as of Aug. 1). A drop in COVID-19 vaccines and treatment has caused a drop in Pfizer's revenue. Pfizer's stock appears to be in bargain territory for long-term investors. 10 stocks we like better than Pfizer › Five years ago, the world was in the thick of the COVID-19 global pandemic, bringing Pfizer (NYSE: PFE) into the spotlight because of the role it played in developing the COVID-19 vaccine with its partner BioNTech. It was able to get U.S. Food and Drug Administration (FDA) approval for its COVID-19 vaccine on Dec. 11, 2020, and it was released on Dec. 14, 2020. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » From mid-2020 to late 2021, Pfizer's stock skyrocketed, but since hitting its peak, it has reversed course. Had you invested $1,000 into Pfizer's stock on Aug. 1, 2020, your investment would only be worth around $638 as of Aug. 1, 2025. Pfizer's dividend would've cushioned some of the blow, but an investment then would still be less than your initial investment, at $828. PFE data by YCharts Why has Pfizer's stock struggled the past few years? Much of Pfizer's stock price troubles since hitting its Dec. 21 peak come down to a decline in demand for its COVID-19 vaccine and treatments, anticipated patent expirations on drugs like Ibrance (breast cancer) and Eliquis (blood clots), and an underwhelming pipeline. All isn't lost with Pfizer's stock, however. At its current levels -- trading at 7.7 times forward earnings -- Pfizer seems to be flirting with bargain territory. I don't expect a quick turnaround, but this low valuation gives it more long-term upside than downside. It also helps that the stock's dividend yield sits above 7.3%, more than 5.5 times the S&P 500 average. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
